ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-L1 Antibody-drug Conjugate HLX43

Also written as “HLX43”, “HLX43 DOSE 1” and “HLX43 DOSE 2”.

In Fosun Pharma’s pipeline, PD-L1 ADC. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Neoplasms · Uterine Cervical Neoplasms · Triple Negative Breast Neoplasms · Breast Neoplasms, led by Fosun Pharma.

Drug pageAnti-PD-L1 Antibody-drug Conjugate HLX43: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 5, 202617 company-led studies, 17 open or runningNext primary completion: Nov 22, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma1717 open or runningphase 3since Mar 5, 2026Oct 30, 2023Nov 22, 2026phase 2 · NCT06839066
  • Named in Fosun Pharma’s own pipeline as HLX43 (PD-L1 ADC), phase 2, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2023First study: phase 1 study in Advanced/Metastatic Malignant Solid TumorsFirst studyNCT06115642 · 367 planned · United States, China, Japan
  2. Dec 16, 2024Phase 2 study in Carcinoma, HepatocellularNCT06742892 · 90 planned · China
  3. Jan 7, 20253 phase 2 studiesNCT06769152, NCT06769113, NCT06848699
  4. Feb 18, 20252 phase 2 studiesNCT06839066, NCT06857279
  5. Mar 26, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06907615 · 243 planned · United States, China
  6. Jul 30, 2025Phase 2 study in Colorectal NeoplasmsNCT07106892 · 60 planned · China
  7. Aug 4, 2025Phase 2 study in Gastric or Gastroesophageal Junction AdenocarcinomaNCT07115485 · 60 planned · China
  8. Nov 19, 20253 phase 2 studiesNCT07253142, NCT07301229, NCT07269782
  9. Jan 14, 2026Phase 2 study in Colonic NeoplasmsNCT07358585 · 126 planned · China
  10. Mar 5, 2026Phase 3 study in Advanced or Metastatic Squamous Non-Small Cell Lung CancerPhase 3 reachedNCT07459751 · 706 planned · China
  11. Mar 5, 20262 phase 2 studies in Breast NeoplasmsNCT07459738, NCT07487519
  12. Oct 13, 2026Primary completion moved from 2026-06-30 to 2026-12-30Date moved laterphase 1 · +6 months · NCT06115642

Ahead

  1. Nov 22, 2026Primary completion: phase 2 study in Nasopharyngeal CarcinomaNCT06839066
  2. Dec 30, 2026Primary completion: phase 2 study in Breast NeoplasmsNCT07459738
  3. Dec 30, 2026Primary completion: phase 2 study in Colorectal NeoplasmsNCT07106892
  4. Dec 30, 2026Primary completion: phase 1 study in Advanced/Metastatic Malignant Solid TumorsNCT06115642

TargetBeta

“PD-L1 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07487519Breast Neoplasms · China2Not yet recruitingMay 15, 2027180
NCT07459751Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · China3RecruitingJan 15, 2030706
NCT07459738Breast Neoplasms2Not yet recruitingDec 30, 202660
NCT07358585Colonic Neoplasms · China2Not yet recruitingJul 28, 2027126
NCT07269782Carcinoma, Non-Small-Cell Lung · China2RecruitingJul 10, 202660
NCT07301229Pancreatic Ductal Adenocarcinoma (PDAC)2Not yet recruitingFeb 21, 2028100
NCT07253142Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 18, 2027120
NCT07115485Gastric or Gastroesophageal Junction Adenocarcinoma · China2RecruitingAug 30, 202760
NCT07106892Colorectal Neoplasms · China2RecruitingDec 30, 202660
NCT06907615Carcinoma, Non-Small-Cell Lung · United States, China2RecruitingApr 20, 2028243
NCT06857279Carcinoma of Head and/or Neck · China2RecruitingDec 30, 2027167
NCT06839066Nasopharyngeal Carcinoma · China2RecruitingNov 22, 202670
NCT06848699Carcinoma, Non-Small-Cell Lung · China2RecruitingOct 30, 2026105
NCT06769152Uterine Cervical Neoplasms · China2RecruitingDec 31, 2026190
NCT06769113Esophageal Neoplasms · China2RecruitingOct 31, 2026102
NCT06742892Carcinoma, Hepatocellular · China2RecruitingOct 31, 202690
NCT06115642Advanced/Metastatic Malignant Solid Tumors · United States, China, Japan1By invitationDec 30, 2026367

How it is read

Names in the registry

  • “HLX43”, 5 entries
  • “HLX43 DOSE 1”, 5 entries
  • “HLX43 DOSE 2”, 5 entries
  • “HLX43 DOSE 3”, 4 entries
  • “HLX43 dose 1”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.